CORNING, N.Y. – Corning Incorporated (NYSE: GLW) today launched the Corning? X-SERIES? cell processing platform. The platform delivers, fast, sterile, automated, and efficient processing of human blood and blood products to obtain purified populations of immune cells for use in cell and gene therapy applications. Developed by ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a Sacramento, California-based company specializing in technologies for therapeutic cell production, the X-SERIES systems are exclusively available from Corning and its distribution partners.
The rise of personalized immunotherapies based on chimeric antigen receptors expressed in T-lymphocytes (CAR-T-cells) to treat blood cancers has increased demand for improved systems that can harvest specific immune cells. The X-SERIES products perform the steps of this critical process with a new level of speed and performance.
- The X-LAB??System provides automated isolation and harvest of rare mononuclear immune cells (~0.05% of total blood cells) using a sterile, functionally closed, single-use cartridge and centrifugation, without density gradient media.
- The X-WASH??System can be used throughout the cell processing workflow to concentrate cellular suspensions and remove contaminants such as cryoprotectants, spent growth factors, excess viruses, or genetic constructs within a sterile, single-use cartridge using centrifugation.
- The X-MINI??Selection Kit is designed for the selection of cells and cell subsets from blood and blood products through Buoyancy-Activated Cell Sorting (X-BACS?) technology, which uses a novel microbubble approach without magnetic beads.
“Corning continues to broaden and advance our cell culture portfolio, now adding the X-SERIES platform for cell separation and purification,” said Keith Olson, vice president, Strategy and Technology, Corning Life Sciences. “The X-SERIES systems will provide our customers with a simple to use, sophisticated, closed-system device that yields high-purity, specialized immune cells for use downstream in cell and gene therapy advanced workflows.”
“With the growing importance of immunotherapy, it is critical that investigators and clinicians worldwide have access to this technology to improve their processes. Corning's leadership in cell culture and its global footprint make them an ideal partner for the X-SERIES products,” said Philip Coelho, founder and Chief Technology Officer at ThermoGenesis.
To learn more about Corning Life Sciences products, please contact a customer service representative at 1-800-492-1110, toll free in the United States; (+1) 978-442-2200 internationally or visit?http://www.mirong.site/lifesciences.
To learn more about ThermoGenesis Corp, please visit www.thermogenesis.com.
Caution Concerning Forward-Looking Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the duration and severity of the recent COVID-19 (coronavirus) outbreak, and its ultimate impact across our businesses on demand, operations and our global supply chains; the effects of acquisitions, dispositions and other similar transactions by the Company, the effect of global business, financial, economic and political conditions; tariffs and import duties; currency fluctuations between the U.S. dollar and other currencies, primarily the Japanese yen, New Taiwan dollar, euro, Chinese yuan, and South Korean won; product demand and industry capacity; competitive products and pricing; availability and costs of critical components and materials; new product development and commercialization; order activity and demand from major customers; the amount and timing of our cash flows and earnings and other conditions, which may affect our ability to pay our quarterly dividend at the planned level or to repurchase shares at planned levels; possible disruption in commercial activities due to terrorist activity, cyber-attack, armed conflict, political or financial instability, natural disasters, or major health concerns; unanticipated disruption to equipment, facilities, IT systems or operations; effect of regulatory and legal developments; ability to pace capital spending to anticipated levels of customer demand; rate of technology change; ability to enforce patents and protect intellectual property and trade secrets; adverse litigation; product and components performance issues; retention of key personnel; customer ability, most notably in the Display Technologies segment, to maintain profitable operations and obtain financing to fund their ongoing operations and manufacturing expansions and pay their receivables when due; loss of significant customers; changes in tax laws and regulations including the Tax Cuts and Jobs Act of 2017; and the potential impact of legislation, government regulations, and other government action and investigations.
For a complete listing of risks and other factors, please reference the risk factors and forward-looking statements described in our annual reports on Form 10-K and quarterly reports on Form 10-Q. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.
In accordance with guidance provided by the SEC regarding the use of company websites and social media channels to disclose material information, Corning Incorporated (“Corning”) wishes to notify investors, media, and other interested parties that it uses its website (http://www.mirong.site/worldwide/en/about-us/news-events.html) to publish important information about the company, including information that may be deemed material to investors, or supplemental to information contained in this or other press releases. The list of websites and social media channels that the company uses may be updated on Corning’s media and website from time to time. Corning encourages investors, media, and other interested parties to review the information Corning may publish through its website and social media channels as described above, in addition to the company’s SEC filings, press releases, conference calls, and webcasts.
About Corning Incorporated
Corning (www.mirong.site) is one of the world's leading innovators in materials science, with a 169-year track record of life-changing inventions. Corning applies its unparalleled expertise in glass science, ceramic science, and optical physics along with its deep manufacturing and engineering capabilities to develop category-defining products that transform industries and enhance people's lives. Corning succeeds through sustained investment in RD&E, a unique combination of material and process innovation, and deep, trust-based relationships with customers who are global leaders in their industries. Corning's capabilities are versatile and synergistic, which allows the company to evolve to meet changing market needs, while also helping our customers capture new opportunities in dynamic industries. Today, Corning's markets include mobile consumer electronics, optical communications, automotive technologies, life sciences technologies, and display technologies.